Companies in #MTAP-Deleted Solid Tumors
Found 1 company operating in this sector.
Tango Therapeutics is a clinical-stage precision oncology biotechnology company headquartered in Boston, Massachusetts, focused on synthetic lethality to target tumor suppressor gene loss, including MTAP deletions. In October 2026, following encouraging ESMO Phase 1/2 clinical combination data for its MTA-cooperative PRMT5 inhibitor vopimetostat paired with Revolution Medicines' RAS(ON) inhibitors in metastatic pancreatic ductal adenocarcinoma (PDAC), Tango cut 14% of its workforce (~19 discovery roles) to halt novel target discovery and concentrate resources on advancing vopimetostat into registrational Phase 3 trials alongside CNS-penetrant PRMT5 inhibitor TNG456.